Skip to content

Matthew McFarlane

Headshot of attorney Matthew McFarlane with grayish blue background.

Matthew McFarlane


[email protected]

212-419-5210, ext. 2

917-698-0363 (mobile)

Matthew McFarlane works in cutting-edge areas where law and science are both continuously breaking new ground, Matthew McFarlane brings exceptional scientific knowledge and legal experience to a practice focused on intellectual property, and patent litigation, representing a diverse client base that includes companies and individuals in the medical, biotechnology, pharmaceutical and chemical technology areas. He is a recognized authority on the emerging face of intellectual property issues, and is frequently quoted in major legal and business periodicals.

In addition to his JD from Fordham University Law School, Mr. McFarlane graduated with honors in Biochemistry from Brown University and subsequently earned a PhD in Molecular & Cellular Physiology from Stanford University School of Medicine. Over the course of his academic career, he authored several scientific publications and received research fellowships from the National Institutes of Health, the Ford Foundation and the American Heart Association.

Mr. McFarlane also has significant pro bono experience, including working through Volunteer Lawyers for the Arts to help artists navigate various legal situations, obtaining a favorable settlement in a federal lawsuit brought by restaurant delivery workers seeking unpaid wages under state and federal labor laws, and representing a Uzbekistan national seeking asylum.


Fordham University School of Law, J.D. (2005)

Stanford University School of Medicine, Ph.D., Molecular & Cellular Physiology; Ford Foundation Predoctoral Fellowship, NIH Predoctoral Fellowship (1997)

Brown University, Sc.B., Biochemistry, with honors; Chemistry Department Award, Ford Foundation Fellowship (1991)

Bar Admissions

New York


Southern District of New York

Eastern District of New York

Federal Circuit Court of Appeals

Professional Associations

New York City Bar Association

New York Intellectual Property Law Association, Board of Directors

Federal Circuit Bar Association

Leadership Council On Legal Diversity, 2012 Fellows Program

Selective Case Results

Counsel in obtaining summary judgment of non-infringement for General Electric in the defense of a patent litigation lawsuit brought by a former GE employee in the United States District Court for the Northern District of Illinois. Technology relates to computer numerical controlled milling machines.

Represented Quest Diagnostics Incorporated in multi-district patent infringement litigation involving Myriad Genetics’ patents for genetic-based tests to detect genes linked to hereditary cancer. Obtained a dismissal of all claims. In re: BRCA1- and BRCA2-Based Hereditary Cancer Test Patent Litigation, No. 2:14-MD-02510-RJS (D. Utah).

Promega Corporation v. Applied Biosystems, LLC, Life Technologies Corporation, and California Institute of Technology: Judge Richard A. Posner ruled in favor of our client, Promega Corporation, in a suit that it initiated against one of its competitors. In an opinion dated June 12, 2013 from the U.S. District Court for the Northern District of Illinois, Judge Posner ruled that certain claims of U.S. Patent No. RE43,096, asserted against Promega, are invalid. Promega prevailed in its arguments that the claims of the ’096 patent were invalid due to the breadth of the claim constructions that Defendants sought and obtained. Certain asserted claims were invalid for lack of written description support. While the patent describes an improvement to DNA sequencing, the breadth of the claims encompassed technologies that Caltech did not invent, including the PCR-based methods on which Promega’s accused products are based. The asserted claims were additionally invalid as anticipated or obvious in view of the prior art, including a prior art patent to Caltech, which expired years ago. Judge Posner also found certain claims invalid for obviousness type double patenting. Defendants appealed various aspects of Judge Posner’s decision and the judgment. Six days after oral argument, the Federal Circuit summarily affirmed the judgment, awarding Promega a complete victory in the case.

Represented a UK-based inventor in a lawsuit seeking declaratory judgment of non-infringement and invalidity of patent claims covering testing methods for Down syndrome during pregnancy.

Represented a Japanese laboratory in a patent infringement lawsuit involving genetically engineered mice.

Represented a domestic agricultural biotechnology company in a patent infringement, patent licensing, and antitrust lawsuit involving genetically modified agricultural products.

Represented a Swiss pharmaceutical company in a patent infringement jury trial and subsequent appeal in a case involving analogs of recombinant therapeutic proteins.

Represented a domestic biotechnology company and Boston-area universities in a patent infringement jury trial and subsequent appeal in a case involving immune system treatment methods.

Represented domestic pharmaceutical companies in a patent litigation involving methods for the recombinant expression of proteins.

Defended a domestic pharmaceutical company in a Hatch-Waxman litigation concerning generic pharmaceutical products.

Provided freedom to operate opinions and pre-litigation counseling for a large domestic biotechnology company concerning therapeutic antibodies.

Represented a large domestic biotechnology company in a patent litigation involving bacterially-produced recombinant therapeutic proteins.

Past results are reported to provide the reader with an indication of the type of litigation we practice. They do not and should not be construed to create an expectation of result in any other case, as all cases are dependent upon their own unique fact situation and applicable law.


Named a “New York Metro Rising Star,” Super Lawyers (2014-2016)

Named a “Life Sciences Star,”LMG Life Sciences (2014-2016)

Pro Bono Service Award,” The Legal Aid Society (2009-2010, 2014)

Being named to the list or receiving the award is not intended and should not be viewed as comparative to other lawyers or to create an expectation about results that might be achieved in a future matter.

In The News

  • Quoted in “Fed. Cir. Denies ‘Dolly’ Clone Rehearing; Supreme Court Only Option Available,” Bloomberg BNA Life Sciences Law & Industry Report (August 15, 2014)
  • Quoted in “Biotech Reels Over Natural Products Ruling,” Scientific American (July 9, 2014)
  • Quoted in “Biotech Reels Over Patent Ruling,” Nature (July 8, 2014) 
  • Quoted in “PTO’s Mayo/Myriad Eligibility Guidance May Chill New Drugs, Diagnostics, Panels Says,” Pharmaceutical Law & Industry Report (July 1, 2014) 
  • Quoted in “Analysis: Myriad, Mayo Fuel Biopharma Patent Rejections,” SCRIP Intelligence (June 27, 2014) 
  • Quoted in “USPTO Extends Deadline to Comment on Subject Matter Eligibility Analysis,” Personalized Medicine Bulletin (June 26, 2014) 
  • Quoted in “Bloomberg BNA Study Analyzes the Impact of Recent Supreme Court Decisions that Leave Life Sciences Industry Under Cloud of Uncertainty: Report Released at 2014 BIO International Convention Explores Important Changes to Patent Process,” BioMedReports, PR Newswire, IT Business Net, Congoo, Bloomberg BNA (June 25, 2014) 
  • Quoted in “PTO’s Mayo/Myriad Eligibility Guidance May Chill New Drugs, Diagnostics, Panel Says,” Bloomberg BNA Medical Research Law & Policy Report (July 2, 2014) 
  • Quoted in “5 Recent Fed. Circ. Rulings IP Attys Need to Know,” Law360 (January 9, 2014) 
  • Quoted in “Stem Cell Patent Case Will be Early Test of Myriad’s Reach,” Law360 (July 10, 2013) 
  • On June 13, 2013, Mr. McFarlane was quoted in numerous publications and news sources for his comment on the Supreme Court’s ruling that isolated human genes cannot be patented.
  • Quoted in “Justices Cast Skeptical Eye on Human Gene Patents,” Law360 (April 15, 2013)


CBS News


Presentations & Publications